What is the next big thing for your company’s portfolio?

To help pharmaceutical companies answer this question, Kaiser Associates conducted a comprehensive analysis of nearly every pharma R&D program in the world and compiled the findings into the Hot Indications List.

 

Their report includes:

Kaiser’s ranking and analysis of the Top 50 indications

4 Therapeutic Area Deep Dives

Oncology

Neurology

Ophthalmology

Gastroenterology

Top 10 Emerging Orphan Diseases

 

You can download the report at this address:

 

http://info.kaiserassociates.com/2015-hot-indications-kaiser-associates?hsCtaTracking=30d30f24-1412-4c24-aac4-52dd4b12d023%7C469656c3-1e5f-483c-b4e6-febe53a2fc4e&mkt_tok=3RkMMJWWfF9wsRonuKzIdu%2FhmjTEU5z14%2B0qXKC1lMI%2F0ER3fOvrPUfGjI4ASMZqM6%2BTFAwTG5toziV8R7LMKM1ty9MQWxTk

 

Source: Kaiser Associates

Leave a Reply